Sarcopenia in Lung Cancer: A Narrative Review
U Jogiat, Z Jimoh, SR Turner, V Baracos… - Nutrition and …, 2023 - Taylor & Francis
It has been over 10 years since the relationship between sarcopenia and lung cancer was
first explored. Since then, sarcopenia research has progressed substantially, and the …
first explored. Since then, sarcopenia research has progressed substantially, and the …
[HTML][HTML] Exposure–response analysis of osimertinib in patients with advanced non-small-cell lung cancer
T Rodier, A Puszkiel, E Cardoso, D Balakirouchenane… - Pharmaceutics, 2022 - mdpi.com
High interindividual variability (IIV) of the clinical response to epidermal growth factor
receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might …
receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might …
[HTML][HTML] Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint …
J Lyu, N Yang, L Xiao, X Nie, J Xiong, Y Liu… - Frontiers in …, 2023 - frontiersin.org
Objectives: In this study, we aimed to assess the association between sarcopenia and
clinical outcomes in patients with advanced NSCLC receiving EGFR-TKIs or ICIs as a first …
clinical outcomes in patients with advanced NSCLC receiving EGFR-TKIs or ICIs as a first …
Impact of muscle mass loss on outcomes in advanced or metastatic gastric cancer patients receiving a second-line treatment
Objective: Sarcopenia is a frequent disorder among cancer patients. It commonly leads to
muscle mass wasting and poor clinical outcomes, even though it is rarely recognized and …
muscle mass wasting and poor clinical outcomes, even though it is rarely recognized and …
[PDF][PDF] 肺癌患者合并肌肉减少症对预后的影响
魏芯芯， 薛伟， 李利廷 - 肿瘤代谢与营养电子杂志 - 182.92.200.144
肺癌是最常见的恶性肿瘤之一. 在国内, 肺癌的死亡率在恶性肿瘤中居于首位,
严重危害我国人民的健康. 如何及时且快速地改善患者生命质量, 延长生命期限 …
严重危害我国人民的健康. 如何及时且快速地改善患者生命质量, 延长生命期限 …